Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Gastroenterology

• Publication date

  2010-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1053/j.gastro.2010.04.052PMID 20451520
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• New Strategies for Blood Donor Screening for Hepatitis B Virus

  2012cited by this paper
• Benefits and risks of interferon therapy for hepatitis B

  2009cited by this paper
• Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa‐2a in HBeAg‐negative patients

  2009cited by this paper
• Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa‐2a in HBeAg‐negative chronic hepatitis B

  2009cited by this paper
• Is exercise beneficial to the inflammatory bowel diseases? An implication of heat shock proteins.

  2009cited by this paper
• Hepatitis B virus DNA levels and outcomes in chronic hepatitis B

  2009cited by this paper
• Early hepatitis B virus DNA reduction in hepatitis B e antigen–positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir

  2009cited by this paper
• The current state of serum biomarkers of hepatotoxicity.

  2008cited by this paper
• Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen–negative chronic hepatitis B virus infection?

  2008cited by this paper
• Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients.

  2007cited by this paper
• Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion

  2007cited by this paper
• Hepatitis B virus DNA prediction rules for hepatitis B e antigen–negative chronic hepatitis B

  2007cited by this paper
• Hepatitis B e Antigen-Negative Chronic Hepatitis B: Natural History and Treatment

  2006cited by this paper
• Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases.

  2006cited by this paper
• Influence of hepatitis B virus genotypes on the intra‐ and extracellular expression of viral DNA and antigens

  2006cited by this paper
• Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.

  2006cited by this paper
• Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years.

  2004cited by this paper
• Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

  2004cited by this paper
• Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms.

  2004cited by this paper
• Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study.

  2003cited by this paper
• Prevalence of HBV precore/core promoter variants in the United States

  2003cited by this paper
• Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study.

  2002cited by this paper
• Chronic hepatitis B

  2001cited by this paper
• [Chronic hepatitis B].

  2001cited by this paper
• Factors predictive of liver cirrhosis in patients with chronic hepatitis B: a multivariate analysis in a longitudinal study

  2000cited by this paper
• Quantitative analysis of IgM anti-HBc in chronic hepatitis B patients using a new "gray-zone" for the evaluation of "borderline" values.

  1996cited by this paper
• The natural history of asymptomatic hepatitis B surface antigen carriers.

  1993cited by this paper
• The Natural History of Asymptomatic Hepatitis B Surface Antigen Carriers

  1993cited by this paper
• Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen

  1989cited by this paper
• Long‐term follow‐up of anti‐HBe‐positive chronic active hepatitis B

  1988cited by this paper
• Occurrence of pre‐S1 antigen in viremic and nonviremic carriers of hepatitis B surface antigen

  1988cited by this paper
• Characterization of pre-s gene products in hepatitis B surface antigen.

  1983cited by this paper
• Variable protein composition of hepatitis B surface antigen from different donors.

  1982cited by this paper

• The Sustainable Goal of Eliminating Hepatitis B, Functional Cure, and the Prospect of NASVAC: A Review.

  2026cites this paper
• Refining surveillance of hepatocellular carcinoma in chronic hepatitis B through biomarker-based risk stratification.

  2026cites this paper
• Functional Cure for Hepatitis B Virus: Challenges and Achievements

  2025cites this paper
• Management of inactive HBsAg carriers: an analysis based on current clinical evidence

  2025cites this paper
• Development and validation of a new predictive model for the immune tolerance stage of chronic HBV infection based on the liver histopathological changes

  2025influential citation
• Hepatitis B surface antigen: carcinogenesis mechanisms and clinical implications in hepatocellular carcinoma

  2025cites this paper
• HBcrAg and cirB‐RNA Do Not Predict Clinical and Virological Outcomes in Patients With HBeAg‐Negative Chronic Infection

  2025cites this paper
• Evolving insights into viral hepatitis: Advances, evidence, and expert perspectives from the ESCMID Study Group for Viral Hepatitis (ESGVH) - Part 2: hepatitis B, C, and delta.

  2025cites this paper
• Long-term Virological and Clinical Evaluation of Chronic Hepatitis B Patients Under Nucleos(t)ide Analogues Therapy.

  2025cites this paper
• EASL Clinical Practice Guidelines on the management of hepatitis B virus infection.

  2025cites this paper
• Individualizing endpoints in chronic HBV treatment: HBsAg loss and beyond.

  2025cites this paper
• Can quantitative surface antigen levels and systemic immune-inflammation index be predictive as a new indicator for the initiation of treatment in chronic hepatitis b?

  2024cites this paper
• Chronic hepatitis B infection in pediatric population: a retrospective study from a tertiary center in North-Eastern Romania

  2024cites this paper
• Impaired HBsAg release and antiproliferative/antioxidant cell regulation by HBeAg‐negative patient isolates reflects an evolutionary process

  2024cites this paper
• Predictive Factors for HBsAg Loss in Chronic HBeAg‐Negative Hepatitis B Virus Infection: Insights From a 5‐Year French Cohort

  2024cites this paper
• Revisiting the natural history of chronic hepatitis B infection.

  2024cites this paper
• Chronic Hepatitis D Virus Infection and Its Treatment: A Narrative Review

  2024cites this paper
• Histological features of chronic hepatitis B patients with normal alanine aminotransferase according to different criteria

  2024cites this paper
• HBsAg level defines different clinical phenotypes of HBeAg(−) chronic HBV infection related to HBV polymerase-specific CD8+ cell response quality

  2024cites this paper
• Research Progress of Pegylated Interferon Therapy for Chronic HBV Infection

  2024cites this paper
• Lifetime risk of liver‐related outcomes and determinants in male inactive carriers of chronic hepatitis B

  2023influential citation
• Perspectives on Outcome Prediction in Patients With Chronic Hepatitis B Virus Infection

  2023cites this paper
• Study on pathological and clinical characteristics of chronic HBV infected patients with HBsAg positive, HBV DNA negative, HBeAg negative

  2023cites this paper
• Use of HBV RNA and to predict change in serological status and disease activity in CHB

  2023cites this paper
• Eligibility for antiviral therapy and treatment uptake in chronic hepatitis B patients referred to a European tertiary care center

  2023cites this paper
• Natural History and Hepatitis B Virus Surface Antigen (HBsAg) Spontaneous Seroclearance in Hepatitis B Virus e-Antigen (HBeAg)-Negative Patients with Inactive Chronic Infection: A Multicenter Regional Study from South Italy

  2023influential citation
• The Circulating miRNA Profile of Chronic Hepatitis D and B Patients Is Comparable but Differs from That of Individuals with HBeAg-Negative HBV Infection

  2023cites this paper
• HBsAg protein composition and clinical outcomes in chronic hepatitis D and variations across HBeAg-negative chronic HBsAg carriers

  2023cites this paper
• HbsAg seviyesinin HBV DNA ve karaciğer fibrozisi ile ilişkisi

  2023cites this paper
• HBeAg-Negative/Anti-HBe-Positive Chronic Hepatitis B: A 40-Year-Old History

  2022cites this paper
• A cautionary note to hepatitis B e antigen (HBeAg)‐negative test results in pregnant women in an area prevalent of HBeAg‐negative chronic hepatitis B

  2022cites this paper
• Review article: novel biomarkers in hepatitis B infection

  2022cites this paper
• qHBsAg for the Identification of Liver Histological Abnormalities in HBeAg-Negative Chronic Hepatitis B Patients with Normal and Mildly Elevated ALT Levels

  2022cites this paper
• A Predictive Model to Evaluate the HbeAg Positivity of Chronic Hepatitis B Virus Patients in Clinics: A Cross-Sectional Study

  2022cites this paper
• The Incidence and the Clinical Significance of the Gray Zone in the Clinical Phases of Chronic Hepatitis B Virus Infection

  2022cites this paper
• Intranasal therapeutic vaccine containing HBsAg and HBcAg for patients with chronic hepatitis B; 18 months follow‐up results of phase IIa clinical study

  2022cites this paper
• Clinical and virological features of chronic hepatitis B in the French national surveillance program, 2008–2012: A cross-sectional study

  2022cites this paper
• ACE Score Identifies HBeAg-negative Inactive Carriers at a Single-point Evaluation, Regardless of HBV Genotype

  2022cites this paper
• HBeAg-negative Patients with Chronic Hepatitis B Virus Infection and Normal Alanine Aminotransferase: Wait or Treat?

  2022cites this paper
• Lower prevalence of hepatic fibrosis in low viremic hepatitis B patients with fluctuating HBV DNA levels

  2022cites this paper
• Virological Treatment Monitoring for Chronic Hepatitis B

  2022cites this paper
• Hematological And Clinical Analysis of Hepatitis B Patients from Quetta, Pakistan

  2022cites this paper
• Large spontaneous HBV DNA fluctuations and potential usefulness of a single-point measurement of combined HBV DNA and quantitative HBsAg for the exclusion of HBeAg-negative chronic hepatitis B: A prospective Tunisian cohort study.

  2022cites this paper
• Inter-method variability of hepatitis B surface antigen quantification in a cohort of Egyptian patients with chronic hepatitis B virus.

  2021cites this paper
• Incremental value of HBcrAg to classify 1582 HBeAg‐negative individuals in chronic infection without liver disease or hepatitis

  2021cites this paper
• Viral and Host Factors Affecting Disease Progression of Hepatitis B Virus Infection

  2021cites this paper
• Minerva Access is the Institutional Repository of The University of Melbourne

  2021cites this paper
• Aiming for Functional Cure With Established and Novel Therapies for Chronic Hepatitis B

  2021cites this paper
• Construction of an anti-hepatitis B virus preS1 antibody and usefulness of preS1 measurement for chronic hepatitis B patients: Anti-HBV PreS1 antibody.

  2021cites this paper
• Treatment of HCV, HDV, or HIV Coinfections

  2021cites this paper
• How to interpret viral markers in the management of chronic hepatitis B infection.

  2021cites this paper
• Diagnosis and treatment of hepatitis B. What contributions can prisons make?

  2021cites this paper
• Clinical utility of quantifying hepatitis B surface antigen in African patients with chronic hepatitis B

  2021cites this paper
• The relationship between hepatitis B virus serum DNA, RNA and quantitative hepatitis B surface antigen, and the predictive value for mother‐to‐child transmission: an observational cohort study

  2021cites this paper
• Mortality of inactive hepatitis B virus carriers in Japan is similar to that of the general population

  2021cites this paper
• Epidemiology and Natural History of Hepatitis B Virus Infection: Time-Dependent Driving Factors of Chronic Hepatitis B Progression

  2021cites this paper
• Controversies in Treating Chronic Hepatitis B virus: The Role of Hepatitis B Virus DNA and Surface Antigen Titer.

  2021cites this paper
• The Role of Elastography in HBV: Assessing Liver Fibrosis

  2021cites this paper
• Baseline Quantitative Hepatitis B Core Antibody Titer Is a Predictor for Hepatitis B Virus Infection Recurrence After Orthotopic Liver Transplantation

  2021cites this paper
• Comparison of HBV RNA and Hepatitis B Core Related Antigen With Conventional HBV Markers Among Untreated Adults With Chronic Hepatitis B in North America

  2021cites this paper
• NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF CHRONIC INFECTION WITH HEPATITIS B VIRUS.

  2021cites this paper
• Monitoring and management of hepatitis B, C, and HIV infection before and after transplantation

  2021cites this paper
• The role of quantitative HBsAg in patients with HBV DNA between 2000–20,000 IU/ml

  2021cites this paper
• The role of quantitative HBsAg in the natural history of e antigen-negative chronic hepatitis B: A Tunisian prospective study.

  2021cites this paper
• A Predict Model to Evaluate the Level of HBV-DNA for the Patients With Chronic Hepatitis B Virus (CHB) in Clinic: a Cross-sectional Study

  2021cites this paper
• Noninvasive Evaluation of Liver Fibrosis in a Sample of Putative Inactive HBV Carriers in Rome, Italy

  2021cites this paper
• Traitement de l’infection virale B

  2021cites this paper
• Expansion of dysfunctional CD56‐CD16+ NK cells in chronic hepatitis B patients

  2020cites this paper
• Examination of Mutations in the HBsAg and Polymerase Genes Induced by Pegylated Interferon Alpha and Oral Antivirals Used in the Treatment of Chronic Hepatitis B

  2020cites this paper
• Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020)

  2020cites this paper
• Analysis of genetic and viral determinants of HBsAg levels in patients with chronic HBV infection.

  2020cites this paper
• Early Serum HBsAg Kinetics as Predictor of HBsAg Loss in Patients with HBeAg-Negative Chronic Hepatitis B after Treatment with Pegylated Interferonα-2a

  2020cites this paper
• Usefulness of quantitative hepatitis B surface antigen testing in hepatitis B community-based screening.

  2020cites this paper
• Do the circulating Pre‐S/S quasispecies influence hepatitis B virus surface antigen levels in the HBeAg negative phase of HBV infection?

  2020cites this paper
• Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020).

  2020cites this paper
• Quadruple mutation GCAC1809-1812TTCT acts as a biomarker in healthy European HBV carriers

  2020cites this paper
• Progression de la Fibrose Hépatique Mesurée par le Fibroscan en Fonction de l’Antigénémie Hbs chez Deux Profils Biologiques de Porteurs Chroniques Inactifs du Virus B

  2020cites this paper
• Analysis of pathological changes and related factors in liver tissue of HBeAg-negative patients with low HBsAg levels

  2020cites this paper
• A predict model to evaluate the HbeAg-positive of Chronic Hepatitis B in clinic: a cross-sectional study

  2020cites this paper
• Early Serum HBsAg Kinetics as Predictor of HBsAg Loss in Patients with HBeAg-Negative Chronic Hepatitis B after Treatment with Pegylated Interferonα-2a

  2020cites this paper
• Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection

  2020cites this paper
• A Cautionary Note to Hepatitis B e ANTIGEN (HBeAg)-Negative Status of Pregnant Women

  2020cites this paper
• Rethinking the inactive carrier state: management of patients with low‐replicative HBeAg‐negative chronic hepatitis B and normal liver enzymes

  2020cites this paper
• HBs Antigen Reduction and Anti-HBs Induction Through the Nasal Administration of a Therapeutic Vaccine Containing HBs and HBc Antigen in Patients with Chronic Hepatitis B Virus Infection

  2020cites this paper
• Serum hepatitis B core‐related antigen is an effective tool to categorize patients with HBeAg‐negative chronic hepatitis B

  2019cites this paper
• Hepatitis B Virus Infection: What Is Current and New.

  2019cites this paper
• Role of HBsAg Testing in the Management of Patients with Chronic HBV

  2019cites this paper
• Predictors of sustained functional cure in hepatitis B envelope antigen‐negative patients achieving hepatitis B surface antigen seroclearance with interferon‐alpha–based therapy

  2019cites this paper
• Next generation sequencing identifies baseline viral mutants associated with treatment response to pegylated interferon in HBeAg-positive chronic hepatitis B

  2019cites this paper
• Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients.

  2019cites this paper
• Taiwan consensus statement on the management of chronic hepatitis B.

  2019cites this paper
• Electronic Health Informatics Data To Describe Clearance Dynamics of Hepatitis B Surface Antigen (HBsAg) and e Antigen (HBeAg) in Chronic Hepatitis B Virus Infection

  2019cites this paper
• New and Old Biomarkers for Diagnosis and Management of Chronic Hepatitis B Virus Infection.

  2019cites this paper
• Association among cytokine profiles of innate and adaptive immune responses and clinical-virological features in untreated patients with chronic hepatitis B

  2019cites this paper
• Evaluation of a logistic regression model for predicting liver necroinflammation in hepatitis B e antigen‐negative chronic hepatitis B patients with normal and minimally increased alanine aminotransferase levels

  2019cites this paper
• Level of Hepatitis B (HB) Core Antibody Associates With Seroclearance of HBV DNA and HB Surface Antigen in HB e Antigen‐Seronegative Patients

  2019cites this paper
• Quantitative HBsAg levels do not identify hepatic fibrosis in HBeAg-negative chronic hepatitis B patients

  2019cites this paper
• The clinical significance of quantitative HBSAG in patients with HBEAG negative chronic hepatitis B

  2019cites this paper
• HBcrAg, pg RNA and HBsAg dynamically supervise the seroconversion of HBsAg with anti-viral therapy "Loss of HBsAg" maybe not a good end-point of anti-viral therapy.

  2019cites this paper
• How to evaluate the HbeAg-positive during the natural course of Chronic Hepatitis B in clinic? A cross-sectional study

  2019cites this paper